

Piotr Rutkowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6664118/publications.pdf>

Version: 2024-02-01

336
papers

47,647
citations

9775

73
h-index

1823

210
g-index

344
all docs

344
docs citations

344
times ranked

36578
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
2	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
3	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
4	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 358-365.	6.3	2,691
5	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
6	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	13.9	2,240
7	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	13.9	1,976
8	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
9	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
10	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2013, 381, 295-302.	6.3	1,144
11	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1480-1492.	5.1	1,089
12	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	13.9	909
13	Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. <i>Lancet Oncology</i> , The, 2012, 13, 265-274.	5.1	790
14	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 901-908.	5.1	487
15	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
16	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	5.1	428
17	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1835-1844.	6.3	423
18	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 435-445.	5.1	399

#	ARTICLE	IF	CITATIONS
19	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). <i>Annals of Surgery</i> , 2016, 263, 1002-1009.	2.1	392
20	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	0.8	364
21	Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1772-1779.	0.8	351
22	Succinate Dehydrogenase-Deficient GISTs. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1712-1721.	2.1	319
23	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
24	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2/3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1148-1159.	5.1	288
25	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287
26	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1366-1377.	5.1	266
27	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	0.8	258
28	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2022, 399, 1718-1729.	6.3	236
29	Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor. <i>Annals of Surgical Oncology</i> , 2007, 14, 2018-2027.	0.7	227
30	Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients. <i>Annals of Surgery</i> , 2008, 248, 949-955.	2.1	225
31	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224
32	Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC-STBSG. <i>Annals of Surgical Oncology</i> , 2012, 19, 2981-2991.	0.7	212
33	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 1389-1398.	5.1	206
34	Molecular Biology of Osteosarcoma. <i>Cancers</i> , 2020, 12, 2130.	1.7	198
35	Prognosis in Patients With Sentinel Node-Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria. <i>Journal of Clinical Oncology</i> , 2011, 29, 2206-2214.	0.8	195
36	Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. <i>Clinical Cancer Research</i> , 2012, 18, 4458-4464.	3.2	194

#	ARTICLE	IF	CITATIONS
37	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	0.8	192
38	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 2937-2943.	0.7	190
39	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	5.1	186
40	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	5.1	183
41	Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. <i>Journal of Surgical Oncology</i> , 2006, 93, 304-311.	0.8	166
42	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	1.3	160
43	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and	0.8	148
44	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , 2017, 35, 1713-1720.	0.8	148
45	Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1719-1729.	5.1	143
46	Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone. <i>Annals of Surgical Oncology</i> , 2015, 22, 2860-2868.	0.7	142
47	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	2.1	142
48	<i>KIT</i> and <i>PDGFRA</i> Mutations and the Risk of GI Stromal Tumor Recurrence. <i>Journal of Clinical Oncology</i> , 2015, 33, 634-642.	0.8	139
49	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Tj ETQq1 1 0.784314 rgBT /Overlock 134 trial. <i>Lancet Respiratory Medicine</i> .the. 2018. 6. 431-441.	5.2	134
50	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	5.1	131
51	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. <i>Clinical Cancer Research</i> , 2014, 20, 6105-6116.	3.2	129
52	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
53	Increased cancer risk of heterozygotes with NBS1 germline mutations in poland. <i>International Journal of Cancer</i> , 2004, 111, 67-71.	2.3	118
54	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9503-9503.	0.8	116

#	ARTICLE	IF	CITATIONS
55	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017, 87, 147-163.	1.3	108
56	Targeted Therapy in Melanoma and Mechanisms of Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4576.	1.8	107
57	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	0.7	105
58	Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transatlantic RPS Working Group. <i>Cancer</i> , 2017, 123, 1971-1978.	2.0	104
59	Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis. <i>Journal of Surgical Oncology</i> , 2003, 84, 151-159.	0.8	102
60	Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation. <i>Journal of Experimental Medicine</i> , 2019, 216, 1061-1070.	4.2	99
61	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 550-560.	5.1	96
62	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
63	Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. <i>Laboratory Investigation</i> , 2007, 87, 1029-1041.	1.7	92
64	Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2006, 13, 1655-1663.	0.7	91
65	Trametinib: a MEK inhibitor for management of metastatic melanoma. <i>OncoTargets and Therapy</i> , 2015, 8, 2251.	1.0	91
66	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for BRAF V600E Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	0.8	90
67	Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-use trial of sunitinib. <i>Cancer</i> , 2015, 121, 1405-1413.	2.0	89
68	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3831-3837.	0.8	88
69	Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy. <i>ESMO Open</i> , 2020, 5, e000970.	2.0	86
70	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
71	Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. <i>Nature Cancer</i> , 2021, 2, 1387-1405.	5.7	83
72	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016, 6, 15.	2.3	80

#	ARTICLE	IF	CITATIONS
73	Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. <i>European Journal of Cancer</i> , 2016, 55, 111-121.	1.3	80
74	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	3.2	80
75	Immunotherapy of melanoma. <i>Wspolczesna Onkologia</i> , 2018, 2018, 61-67.	0.7	78
76	External validation of a multi-institutional retroperitoneal sarcoma nomogram. <i>Cancer</i> , 2016, 122, 1417-1424.	2.0	77
77	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
78	Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes – one institution's experience. <i>Melanoma Research</i> , 2003, 13, 35-43.	0.6	73
79	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019, 125, 1290-1300.	2.0	71
80	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1384-1390.	0.5	70
81	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). <i>Current Signal Transduction Therapy</i> , 2014, 8, 219-228.	0.3	67
82	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64
83	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
84	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 109, 61-69.	1.3	63
85	The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. <i>BMC Cancer</i> , 2012, 12, 107.	1.1	62
86	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	1.9	62
87	The Megavoltage Radiation Therapy in Treatment of Patients With Advanced or Difficult Giant Cell Tumors of Bone. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 494-498.	0.4	61
88	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	1.3	61
89	Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. <i>European Journal of Cancer</i> , 2018, 96, 25-33.	1.3	59
90	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020, 16, 4429-4438.	1.1	59

#	ARTICLE	IF	CITATIONS
91	Small bowel tumors detected and missed during capsule endoscopy: Single center experience. World Journal of Gastroenterology, 2013, 19, 9043.	1.4	59
92	Surgery Combined With Intraoperative Brachytherapy in the Treatment of Retroperitoneal Sarcomas. Annals of Surgical Oncology, 2006, 13, 245-252.	0.7	58
93	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. Annals of Surgical Oncology, 2012, 19, 1551-1559.	0.7	57
94	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. Journal of Clinical Oncology, 2021, 39, 3128-3139.	0.8	56
95	Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate – The impact of fibrosarcomatous transformation. European Journal of Surgical Oncology, 2017, 43, 1134-1141.	0.5	55
96	Defining Tumor Rupture in Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 2019, 26, 1669-1675.	0.7	54
97	The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2–pT3). Annals of Surgical Oncology, 2008, 15, 2223-2234.	0.7	52
98	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer, 2016, 16, 22.	1.1	52
99	IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. Journal of Cancer, 2018, 9, 998-1005.	1.2	50
100	Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors. Cancer, 2011, 117, 4916-4924.	2.0	47
101	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. European Journal of Cancer, 2020, 125, 114-120.	1.3	47
102	Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncology, The, 2009, 10, 157-163.	5.1	46
103	ECCO essential requirements for quality cancer care: Melanoma. Critical Reviews in Oncology/Hematology, 2018, 122, 164-178.	2.0	41
104	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
105	Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 Years. Annals of Surgical Oncology, 2021, 28, 1700-1709.	0.7	38
106	Melanoma without a Detectable Primary Site with Metastases to Lymph Nodes. Dermatologic Surgery, 2010, 36, 868-876.	0.4	37
107	Advances in Molecular Characterization and Targeted Therapy in Dermatofibrosarcoma Protuberans. Sarcoma, 2011, 2011, 1-6.	0.7	37
108	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	5.1	37

#	ARTICLE	IF	CITATIONS
109	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.. Journal of Clinical Oncology, 2022, 40, 9522-9522.	0.8	37
110	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 â€œCREATEâ€™. European Journal of Cancer, 2018, 94, 156-167.	1.3	35
111	Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. International Journal of Biochemistry and Cell Biology, 2014, 53, 505-513.	1.2	34
112	Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. Oncology Letters, 2014, 8, 47-54.	0.8	34
113	Current treatment options for dermatofibrosarcoma protuberans. Expert Review of Anticancer Therapy, 2015, 15, 901-909.	1.1	34
114	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist, 2019, 24, 110-116.	1.9	34
115	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). Cancer Research, 2017, 77, CT075-CT075.	0.4	34
116	Serum markers in early-stage and locally advanced melanoma. Tumor Biology, 2015, 36, 8277-8285.	0.8	33
117	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
118	Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047). Journal of Clinical Oncology, 2022, 40, 360385-360385.	0.8	33
119	Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treatment Reviews, 2014, 40, 242-247.	3.4	32
120	Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). Cancer, 2018, 124, 1449-1454.	2.0	32
121	Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. , 2020, 8, e001117.		32
122	Epithelioid Sarcomaâ€”From Genetics to Clinical Practice. Cancers, 2020, 12, 2112.	1.7	32
123	Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). Journal of Cancer Research and Clinical Oncology, 2007, 133, 589-597.	1.2	31
124	Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers, 2021, 13, 2390.	1.7	31
125	Prognostic Value of Multiple Reverse Transcription-PCR Tyrosinase Testing for Circulating Neoplastic Cells in Malignant Melanoma. Clinical Chemistry, 2003, 49, 1450-1457.	1.5	30
126	Rectal gastrointestinal stromal tumors associated with a novel germline <i>KIT</i> mutation. International Journal of Cancer, 2008, 122, 2160-2164.	2.3	30

#	ARTICLE	IF	CITATIONS
127	Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival. <i>European Journal of Cancer</i> , 2016, 67, 164-173.	1.3	30
128	Long-term Results of Therapy with Sunitinib in Metastatic Alveolar Soft Part Sarcoma. <i>Tumori</i> , 2017, 103, 231-235.	0.6	30
129	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	2.0	30
130	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	1.9	29
131	Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2166-2172.	0.5	29
132	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone. <i>Oncology Letters</i> , 2016, 12, 4312-4318.	0.8	28
133	Differences in recurrence and survival of extremity liposarcoma subtypes. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1391-1397.	0.5	28
134	Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases. <i>Tumor Biology</i> , 2012, 33, 2245-2253.	0.8	27
135	Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2014, 27, 1510-1520.	2.9	27
136	Novel methods of image description and ensemble of classifiers in application to mammogram analysis. <i>Expert Systems With Applications</i> , 2017, 81, 67-78.	4.4	27
137	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	1.3	27
138	SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. <i>European Journal of Cancer</i> , 2020, 137, 175-182.	1.3	27
139	Gastrointestinal Stromal Tumors. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 131-143.	1.6	26
140	Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy. <i>European Journal of Cancer</i> , 2015, 51, 75-83.	1.3	26
141	Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1124-1130.	0.5	26
142	TP53 in Biology and Treatment of Osteosarcoma. <i>Cancers</i> , 2021, 13, 4284.	1.7	26
143	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	0.7	26
144	Candidate diagnostic miRNAs that can detect cancer in prostate biopsy. <i>Prostate</i> , 2018, 78, 178-185.	1.2	24

#	ARTICLE	IF	CITATIONS
145	Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. <i>Postepy Dermatologii I Alergologii</i> , 2019, 36, 382-391.	0.4	24
146	Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site. <i>Annals of Surgical Oncology</i> , 2014, 21, 4317-4323.	0.7	23
147	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015, 51, 852-860.	1.3	23
148	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5077.	1.8	23
149	Developments in Targeted Therapy of Advanced Gastrointestinal Stromal Tumors. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 88-99.	0.8	23
150	Downstream and Intermediate Interactions of Synovial Sarcoma-Associated Fusion Oncoproteins and Their Implication for Targeted Therapy. <i>Sarcoma</i> , 2012, 2012, 1-13.	0.7	22
151	Follow-up in soft tissue sarcomas. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 92-96.	0.3	22
152	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020, 5, e000787.	2.0	22
153	Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall: Results of a Single-Arm Prospective Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 2471.	1.0	22
154	Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression. <i>BMC Cancer</i> , 2009, 9, 413.	1.1	21
155	What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?. <i>Medical Oncology</i> , 2013, 30, 765.	1.2	20
156	Combined Therapy of Gastrointestinal Stromal Tumors. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 735-759.	0.6	20
157	Neoadjuvant Treatment Options in Soft Tissue Sarcomas. <i>Cancers</i> , 2020, 12, 2061.	1.7	20
158	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6305.	1.8	20
159	Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications. <i>Medical Oncology</i> , 2014, 31, 109.	1.2	19
160	Functional outcome of surgical treatment of adults with extremity osteosarcoma after megaprosthesis: single-center experience. <i>Journal of Orthopaedic Surgery and Research</i> , 2019, 14, 346.	0.9	19
161	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 7854-7863.	0.7	19
162	Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. <i>Medical Oncology</i> , 2012, 29, 2966-2977.	1.2	18

#	ARTICLE	IF	CITATIONS
163	Etoposide and carboplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 40-44.	0.8	18
164	Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. <i>Targeted Oncology</i> , 2019, 14, 729-742.	1.7	18
165	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
166	Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	1.3	18
167	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9524-9524.	0.8	17
168	Surgery of Primary Melanomas. <i>Cancers</i> , 2010, 2, 824-841.	1.7	16
169	Management of the "Other" retroperitoneal sarcomas. <i>Journal of Surgical Oncology</i> , 2018, 117, 79-86.	0.8	16
170	Detection of Melanoma Cells in the Lymphatic Drainage after Lymph Node Dissection in Melanoma Patients by Using Two-Marker Reverse Transcriptase-Polymerase Chain Reaction Assay. <i>Annals of Surgical Oncology</i> , 2004, 11, 988-997.	0.7	15
171	Surgery Quality and Tumor Status Impact on Survival and Local Control of Resectable Liposarcomas of Extremities or the Trunk Wall. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 860-870.	0.7	15
172	Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1249-1258.	1.0	15
173	Feasibility and Long-Term Efficacy of PEComa Treatment"20 Years of Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 2200.	1.0	15
174	The safety of regorafenib for the treatment of gastrointestinal stromal tumors. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 105-116.	1.0	14
175	Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage. <i>World Journal of Surgical Oncology</i> , 2019, 17, 129.	0.8	14
176	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	0.6	14
177	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 6882-6889.	0.7	14
178	Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1053-1063.	0.4	14
179	Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series. <i>BMC Cancer</i> , 2017, 17, 717.	1.1	13
180	Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study. <i>Postepy Dermatologii I Alergologii</i> , 2019, 36, 566-571.	0.4	13

#	ARTICLE	IF	CITATIONS
181	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	1.3	13
182	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. <i>Cancers</i> , 2020, 12, 3131.	1.7	13
183	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	1.3	13
184	Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of Patients. <i>Frontiers in Oncology</i> , 2020, 10, 993.	1.3	13
185	Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. <i>Tumori</i> , 2020, 106, 241-248.	0.6	13
186	Mutation profile of primary subungual melanomas in Caucasians. <i>Oncotarget</i> , 2020, 11, 2404-2413.	0.8	13
187	Value of planar lymphoscintigraphy (PL) versus SPECT/CT in evaluation of sentinel lymph node in trunk melanoma – one center, large series retrospective study. <i>Nuclear Medicine Review</i> , 2018, 21, 79-84.	0.3	13
188	Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. <i>Melanoma Research</i> , 2008, 18, 246-252.	0.6	12
189	Other Targetable Sarcomas. <i>Seminars in Oncology</i> , 2009, 36, 358-371.	0.8	12
190	Is the Surgical Margin in Gastrointestinal Stromal Tumors Different?. <i>Visceral Medicine</i> , 2018, 34, 347-352.	0.5	12
191	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020, 65, 316-323.	0.9	12
192	Signatures of circulating microRNA in four sarcoma subtypes. <i>Journal of Cancer</i> , 2020, 11, 874-882.	1.2	12
193	BRAF inhibition curtails IFN γ -inducible PD $\text{-}1$ expression and upregulates the immunoregulatory protein galectin $\text{-}1$ in melanoma cells. <i>Molecular Oncology</i> , 2020, 14, 1817-1832.	2.1	12
194	Efficacy of Sirolimus Treatment in PEComa – 10 Years of Practice Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 3705.	1.0	12
195	Diagnosis strategy of adipocytic soft-tissue tumors in adults: a consensus from European experts. <i>European Journal of Surgical Oncology</i> , 2022, 48, 518-525.	0.5	12
196	Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence. <i>Cancers</i> , 2022, 14, 2290.	1.7	12
197	Cutaneous melanoma with nodal metastases in elderly people. <i>International Journal of Dermatology</i> , 2010, 49, 907-913.	0.5	11
198	Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors. <i>Molecular Diagnosis and Therapy</i> , 2013, 17, 9-19.	1.6	11

#	ARTICLE	IF	CITATIONS
199	Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. <i>Wspolczesna Onkologia</i> , 2013, 3, 257-262.	0.7	11
200	Surgical management of metastatic gastrointestinal stromal tumour. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1295-1300.	0.5	11
201	Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib. <i>Tumori</i> , 2018, 104, 415-422.	0.6	11
202	The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2020, 27, 3659-3671.	0.7	11
203	Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. <i>European Journal of Cancer</i> , 2021, 157, 291-300.	1.3	11
204	Efficacy and Economic Value of Adjuvant Imatinib for Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2013, 18, 689-696.	1.9	10
205	Genetics of rare mesenchymal tumors: Implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 466-474.	1.2	10
206	The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. <i>World Journal of Surgical Oncology</i> , 2015, 13, 299.	0.8	10
207	Melanoma Early Detection and Awareness. <i>American Journal of Therapeutics</i> , 2015, 22, 37-43.	0.5	10
208	The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*. <i>Wspolczesna Onkologia</i> , 2017, 21, 285-289.	0.7	10
209	Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). <i>Journal of Geriatric Oncology</i> , 2018, 9, 520-525.	0.5	10
210	Coordinated expression and genetic polymorphisms in Grainyhead-like genes in human non-melanoma skin cancers. <i>BMC Cancer</i> , 2018, 18, 23.	1.1	10
211	Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. <i>Surgical Oncology</i> , 2019, 29, 84-89.	0.8	10
212	Detection of SS18-SSX1/2 fusion transcripts in circulating tumor cells of patients with synovial sarcoma. <i>Diagnostic Pathology</i> , 2019, 14, 24.	0.9	10
213	Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2996.	1.0	10
214	The Management of Radiation-Induced Sarcomas: A Cohort Analysis from a Sarcoma Tertiary Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 694.	1.0	10
215	Efficacy and Safety of Hypofractionated Preoperative Radiotherapy for Primary Locally Advanced Soft Tissue Sarcomas of Limbs or Trunk Wall. <i>Cancers</i> , 2021, 13, 2981.	1.7	10
216	Treatment Algorithms in Stage IV Melanoma. <i>American Journal of Therapeutics</i> , 2015, 22, 61-67.	0.5	9

#	ARTICLE	IF	CITATIONS
217	Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1107-1116.	1.1	9
218	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. <i>Melanoma Research</i> , 2018, 28, 435-441.	0.6	9
219	Molecular Comparison of Imatinib-Na ⁺ ve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs. <i>Cancers</i> , 2019, 11, 882.	1.7	9
220	The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1191-1195.	0.5	9
221	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4759.	1.8	9
222	Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors – A Sarcoma Reference Center Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 3157.	1.0	9
223	Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 8487-93.	0.5	9
224	545 – A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)., 2021, 9, A574-A575.		9
225	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 – CREATE Trial. <i>Cancers</i> , 2021, 13, 6057.	1.7	9
226	Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay in Lymphatic Drainage and Sentinel Node Tumor Burden. <i>Annals of Surgical Oncology</i> , 2010, 17, 3314-3323.	0.7	8
227	Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. <i>Wspolczesna Onkologia</i> , 2012, 6, 532-545.	0.7	8
228	Follow-up in melanoma patients. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 83-86.	0.3	8
229	A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma. <i>Tumori</i> , 2020, 106, NP9-NP13.	0.6	8
230	Effective treatment of recurrent, advanced dermatofibrosarcoma protuberans by electrochemotherapy. <i>European Journal of Dermatology</i> , 2013, 23, 260-261.	0.3	8
231	Molecular biology of sarcoma. <i>Oncology in Clinical Practice</i> , 2019, 14, 307-330.	0.1	8
232	Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9535-9535.	0.8	8
233	Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9505-9505.	0.8	8
234	Rational combination of cancer immunotherapy in melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 433-447.	1.4	7

#	ARTICLE	IF	CITATIONS
235	Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis. <i>Cells</i> , 2021, 10, 366.	1.8	7
236	The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas. <i>Cancers</i> , 2021, 13, 1332.	1.7	7
237	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9509-9509.	0.8	7
238	What is the best front-line approach in patients with desmoid fibromatosis? â€œ A retrospective analysis from a reference center. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2602-2608.	0.5	7
239	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1949-1958.	2.0	7
240	Ultrasound-Guided Trans-Uterine Cavity Core Needle Biopsy of Uterine Myometrial Tumors to Differentiate Sarcoma from a Benign Lesionâ€™Description of the Method and Review of the Literature. <i>Diagnostics</i> , 2022, 12, 1348.	1.3	7
241	Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9500-LBA9500.	0.8	7
242	News from the melanoma sessions of the European Cancer Congress 2017. <i>BMC Medicine</i> , 2017, 15, 57.	2.3	6
243	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021, 13, 297-307.	1.0	6
244	Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype. <i>Cancers</i> , 2021, 13, 1317.	1.7	6
245	Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 969.	1.8	6
246	Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110706.	1.4	6
247	Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patientsâ€™Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2239.	1.0	6
248	Modern Dressings in Prevention and Therapy of Acute and Chronic Radiation Dermatitisâ€™A Literature Review. <i>Pharmaceutics</i> , 2022, 14, 1204.	2.0	6
249	Denosumab for treating giant cell tumor of bone. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1219-1229.	0.5	5
250	Basal cell carcinoma. Diagnostic and therapeutic recommendations of Polish Dermatological Society. <i>Przegląd Dermatologiczny</i> , 2019, 106, 107-126.	0.0	5
251	Health-related quality of life in patients with fully resected BRAFV600 mutationâ€™positive melanoma receiving adjuvant vemurafenib. <i>European Journal of Cancer</i> , 2019, 123, 155-161.	1.3	5
252	Defining Rupture in Gastrointestinal Stromal Tumor: Semantics and Prognostic Value. <i>Annals of Surgical Oncology</i> , 2019, 26, 2304-2305.	0.7	5

#	ARTICLE	IF	CITATIONS
253	Pigmented/melanocytic malignant perivascular epithelioid cell tumor with TFE3-SFPQ(PSF) rearrangement – a challenging diagnosis of PEComa family of tumors. Polish Journal of Pathology, 2019, 70, 317-322.	0.1	5
254	The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma. International Journal of Clinical Oncology, 2020, 25, 2006-2014.	1.0	5
255	An update on the safety of nivolumab for the treatment of advanced melanoma. Expert Opinion on Drug Safety, 2020, 19, 409-421.	1.0	5
256	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. Journal of Dermatological Treatment, 2022, 33, 2168-2174.	1.1	5
257	Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma. Cancers, 2022, 14, 110.	1.7	5
258	Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in <i>BRAF</i> ^{V600} mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.. Journal of Clinical Oncology, 2022, 40, 9547-9547.	0.8	5
259	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.. Journal of Clinical Oncology, 2022, 40, 9540-9540.	0.8	5
260	Introduction to the special issue of European Journal of Surgical Oncology: New roads in melanoma management. European Journal of Surgical Oncology, 2017, 43, 513-516.	0.5	4
261	Gastrointestinal Stromal Tumors. Visceral Medicine, 2018, 34, 376-379.	0.5	4
262	Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. Oncology Letters, 2019, 18, 3373-3380.	0.8	4
263	Malignant peripheral nerve sheath tumors – Outcomes and prognostic factors based on the reference center experience. Surgical Oncology, 2020, 35, 276-284.	0.8	4
264	Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients. Drugs and Aging, 2021, 38, 375-396.	1.3	4
265	Clinical Significance of Tumor Microenvironment in Acral Melanoma: A Large Single-Institution Study of Caucasians. Journal of Clinical Medicine, 2021, 10, 1452.	1.0	4
266	ASO Visual Abstract: An Analysis of Differentiation Changes and Outcomes at the First Recurrence of Retroperitoneal Liposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals of Surgical Oncology, 2021, 28, 490-491.	0.7	4
267	Characterization and Clinical Utility of BRAFV600 Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma. Cancers, 2021, 13, 3591.	1.7	4
268	Age as a Prognostic Factor in Patients with Ewing Sarcoma – The Polish Sarcoma Group Experience. Journal of Clinical Medicine, 2021, 10, 3627.	1.0	4
269	Polish clinical practice guideline on hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery in peritoneal malignancy treatment. Current Gynecologic Oncology, 2014, 12, 86-97.	0.1	4
270	Standardy leczenia 1/4ywnieniowego w onkologii. Nowotwory, 2015, 65, 320-337.	0.1	4

#	ARTICLE	IF	CITATIONS
271	Merkel cell carcinoma (MCC) – neuroendocrine skin cancer. Nowotwory, 2019, 69, 111-116.	0.1	4
272	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. Melanoma Research, 2021, 31, 49-57.	0.6	4
273	Mutational landscape of primary and recurrent Ewing sarcoma. Wspolczesna Onkologia, 2021, 25, 241-248.	0.7	4
274	Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective. Cancers, 2022, 14, 998.	1.7	4
275	Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti-PD-1 therapy: MASTERKEY-115.. Journal of Clinical Oncology, 2022, 40, 9518-9518.	0.8	4
276	Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients. Cancers, 2022, 14, 2831.	1.7	4
277	The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. Wspolczesna Onkologia, 2015, 4, 280-283.	0.7	3
278	Spotlight on landmark oncology trials: the latest evidence and novel trial designs. BMC Medicine, 2017, 15, 111.	2.3	3
279	TP53-Deficient Angiosarcoma Expression Profiling in Rat Model. Cancers, 2020, 12, 1525.	1.7	3
280	Skin carcinomas. Oncology in Clinical Practice, 2020, 16, 143-162.	0.1	3
281	Treatment of Locally Advanced Merkel Cell Carcinoma – A Multi-Center Study. Cancers, 2022, 14, 422.	1.7	3
282	The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. Cancers, 2022, 14, 777.	1.7	3
283	Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. Cancers, 2022, 14, 1248.	1.7	3
284	Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2022, 40, 101-101.	0.8	3
285	The Outcome of Targeted Therapy in Advanced Gastrointestinal Stromal Tumors (Gist) with Non-Exon 11 Kit Mutations. Polski Przegląd Chirurgiczny, 2014, 86, 325-32.	0.2	2
286	Genetic polymorphisms may influence the vertical growth rate of melanoma. Journal of Cancer, 2018, 9, 3078-3083.	1.2	2
287	Squamous cell carcinoma and Merkel-cell carcinoma. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Przegląd Dermatologiczny, 2019, 106, 127-149.	0.0	2
288	Hyperpolarized ¹³ C tracers: Technical advancements and perspectives for clinical applications. Biocybernetics and Biomedical Engineering, 2021, 41, 1466-1485.	3.3	2

#	ARTICLE	IF	CITATIONS
289	Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2021, 39, e21514-e21514.	0.8	2
290	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. European Journal of Surgical Oncology, 2021, 47, 2173-2181.	0.5	2
291	Sarcoma of the uterus: diagnostic and therapeutic recommendations. Current Gynecologic Oncology, 2013, 11, 24-32.	0.1	2
292	Mechanisms of melanoma resistance to treatment with BRAF and MEK inhibitors. Nowotwory, 2019, 69, 133-141.	0.1	2
293	Why do we need a new BRAF-MEK inhibitor combination in melanoma?. Oncology in Clinical Practice, 2019, 15, 115-119.	0.1	2
294	Mucosal melanoma " clinical presentation and treatment based on a case series. Oncology in Clinical Practice, 2019, 15, 223-230.	0.1	2
295	Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. Cancers, 2022, 14, 2123.	1.7	2
296	Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial. International Journal of Molecular Sciences, 2022, 23, 5689.	1.8	2
297	Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated <i>BRAF</i> V600"mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.. Journal of Clinical Oncology, 2022, 40, 9527-9527.	0.8	2
298	Trabectedin in patients with pre-treated advanced soft tissue sarcoma: a retrospective single center analysis. Wspolczesna Onkologia, 2011, 6, 367-371.	0.7	1
299	Treatment results of adult patients with primary bone tumours of the humerus with the use of the oncological modular endoprosthesis. Wspolczesna Onkologia, 2017, 3, 228-231.	0.7	1
300	Advances in the management of giant cell tumor of bone: current options and future challenges. Expert Opinion on Orphan Drugs, 2018, 6, 553-561.	0.5	1
301	New Therapies in Advanced Cutaneous Malignancies: Conclusions. , 2021, , 441-448.		1
302	Why We Still Need the Better Risk Classification for GIST. Annals of Surgical Oncology, 2021, 28, 2425-2427.	0.7	1
303	Reply to E. Hindi"©. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
304	Treatment beyond progression with immune checkpoint inhibitors in advanced melanoma.. Journal of Clinical Oncology, 2021, 39, e21541-e21541.	0.8	1
305	Venous thromboembolism prophylaxis in cancer patients " guidelines focus on surgical patients. Acta Angiologica, 2017, 22, 71-102.	0.2	1
306	Zalecenia dotycz"ce leczenia chorych na raka podstawnok"rkowego i na raka kolczystok"rkowego przygotowane przez Sekcj" Onkologiczn" Polskiego Towarzystwa Dermatologicznego i sekcj" Akademia Czerniaka Polskiego Towarzystwa Chirurgii Onkologicznej. Nowotwory, 2016, 66, 35-44.	0.1	1

#	ARTICLE	IF	CITATIONS
307	Vismodegib in the treatment of basal cell carcinoma – Polish clinical experience in the frame of therapeutic program. <i>Oncology in Clinical Practice</i> , 2019, 15, 139-149.	0.1	1
308	Badania kontrolne po leczeniu w najczymstszycch nowotworach litych u doroslych. <i>Nowotwory</i> , 2014, 64, 415-435.	0.1	1
309	Talimogen laherparepwek (T-VEC) – nowa terapia czerniakw skory zmodyfikowanym genetycznie wirusem onkologicznym. <i>Nowotwory</i> , 2016, 66, 234-237.	0.1	1
310	Sequential treatment with targeted and immune checkpoint inhibitor therapies in patients with BRAF positive metastatic melanoma: Real-world data.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21539-e21539.	0.8	1
311	In search of effective therapies: the current landscape of phase II trials in patients with advanced soft tissue sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
312	Cutaneous melanoma – guidelines for diagnostics and therapy in 2016. <i>Przegląd Dermatologiczny</i> , 2016, 1, 1-18.	0.0	0
313	ASO Author Reflections: The Importance of Defining Tumor Rupture in GIST Before Research. <i>Annals of Surgical Oncology</i> , 2019, 26, 684-685.	0.7	0
314	Quiz. What is your diagnosis?. <i>Polish Journal of Pathology</i> , 2019, 70, 232-233.	0.1	0
315	The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3129.	1.0	0
316	Detection of Melanoma Cells in Lymphatic Drainage (LD) After Lymph Nodes Dissection Via Nested RT-PCR Analysis of Molecular Melanocytic Markers. <i>Methods in Molecular Biology</i> , 2021, 2265, 377-384.	0.4	0
317	Neoadjuvant and Adjuvant Therapies of Melanoma. , 2021, , 401-415.		0
318	Peripheral Blood Cells from Patients with Hodgkin’s and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs. <i>BioMed Research International</i> , 2021, 2021, 1-9.	0.9	0
319	Systemic treatment of patients with inoperable and metastatic Merkel cell carcinoma: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21521-e21521.	0.8	0
320	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10568.	1.8	0
321	Gene Signatures in Gastrointestinal Stromal Tumors. , 2012, , 35-50.		0
322	Zastosowanie wemurafenibu u chorych na uoglnionego czerniaka z obecnoaci... mutacji w genie BRAF – wybrane przypadki kliniczne. <i>Nowotwory</i> , 2014, 64, 1-19.	0.1	0
323	Zasady stosowania dootrzewnowej chemioterapii w hipertermii (HIPEC) w leczeniu nowotworw w zolowych powierzchni otrzewnej w poczeniu z zabiegami cytoredukcyjnymi: zalecenia krajowe. <i>Nowotwory</i> , 2015, 64, 518-524.	0.1	0
324	Czerniaki skory – zasady postpowania diagnostyczno-terapeutycznego w 2016 roku. <i>Nowotwory</i> , 2016, 65, 501-516.	0.1	0

#	ARTICLE	IF	CITATIONS
325	Skuteczność i bezpieczeństwo stosowania trabectedyny w leczeniu pacjentów, u których rozpoznano zaawansowane tłuszczakomiaki i mięśniaki gładkokomórkowe (L-miaki). <i>Nowotwory</i> , 2016, 65, 451-457.		0
326	Czas przeżycia wolnego od progresji choroby nie jest wiarygodnym kryterium oceny wartości przeciwnowotworowego leczenia systemowego. <i>Nowotwory</i> , 2016, 66, 68-69.	0.1	0
327	Wyniki leczenia wemurafenibem chorych na zaawansowanego czerniaka w ramach programu lekowego w Polsce. <i>Nowotwory</i> , 2016, 66, 118-126.	0.1	0
328	Perspective towards the clinical application of eribulin in soft tissue sarcomas. <i>Translational Cancer Research</i> , 2016, 5, S858-S861.	0.4	0
329	Sentinel lymph node biopsies in patients with malignant melanoma – qualifying principles and histopathological assessment (2017). <i>Nowotwory</i> , 2017, 67, 41-47.	0.1	0
330	Progress in adjuvant treatment of melanoma patients. <i>Nowotwory</i> , 2018, 68, 140-145.	0.1	0
331	Trabectedin in the treatment of patients with soft tissue sarcoma. <i>Nowotwory</i> , 2018, 68, 127-131.	0.1	0
332	Editorial to the Special Issue on Skin Cancer: The State of the Art. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3806.	1.8	0
333	The “Great Debate” at Melanoma Bridge 2021, December 2nd-4th, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, 200.	1.8	0
334	Comparison of prognostic reliability of TNM staging systems version 7/8 and SARCULATOR in primary localized liposarcomas of the extremity or trunk wall. <i>Journal of Clinical Oncology</i> , 2022, 40, e23529-e23529.	0.8	0
335	The long-term analysis of prognostic role of mutational status in primary resectable gastrointestinal stromal tumors (GIST). <i>Journal of Clinical Oncology</i> , 2022, 40, e23517-e23517.	0.8	0
336	Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?. <i>Journal of Clinical Oncology</i> , 2022, 40, e21544-e21544.	0.8	0